Tumor distribution of a theoretical trastuzumab-based RIT was simulated at a dose of 140 μg/kg, which is the maximum tolerated dose for an anti-mesothelin RIT that is currently being evaluated in clinical trials (Hassan et al., 2020). This evidence concerns the gene MSLN and neoplasm.